The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting ...

Novo Nordisk launches Ozempic in India, a type 2 diabetes treatment with weight-loss benefits, starting at ₹2,200 per week.

With this launch, Ozempic now available in India as a once-weekly injectable formulation of semaglutide. It will be available in a pen format in 0.25 mg, 0.5 mg and 1 mg doses in the country.

Looking to expand its footprint in the booming glucagon-like peptide (GLP-1) market, Danish drugmaker Novo Nordisk has ...

Ozempic is now available in India as 0.25 mg, 0.5 mg and 1 mg in 'FlexTouch Pen' - an easy-to-use, once-weekly pen device, at ...

The launch comes amid the company’s legal battle with Indian drugmakers, including Dr Reddy’s Laboratories and Sun Pharma, ...

Novo Nordisk has launched Ozempic, its once-weekly semaglutide injection, in India with prices starting at Rs 8,800. Approved ...

Ozempic is finally here — but it doesn’t come cheap. With costs touching ₹11,000 a month and generics still a year away, here ...

Ozempic, a GLP-1 receptor agonist, has officially launched in India, offering a new treatment option for type 2 diabetes.

CHENNAI: Novo Nordisk has introduced Ozempic, its once-weekly injectable semaglutide, to the Indian market on Friday. Designed as an adjunct to diet and exercis ...

Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with uncontrolled Type 2 diabetes mellitus (T2DM).